Sort
48,018 grants matching “immunotherapy”
UNIVERSITY OF P.R PEDIATRIC AIDS CLINICAL TRIALS UNIT
$867,789University Of Puerto Rico Med Sciences · U01 · FY2004 · AI
Center for Cell-based Therapy - Cures
$867,748Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Posttranscriptional control of gene expression
$867,531Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
$867,492Jyothi Rengarajan · Emory University · R01 · FY2023 · AI
Immunology of aging and immunotherapy of aging-associated diseases
$867,489Arya Biragyn · National Institute On Aging · ZIA · FY2024 · AG
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma
$867,485University Of Pennsylvania · R01 · FY2001 · CA
Bay Area Tumor Institute NCI Community Oncology Research Program (NCORP) Community Sites
$867,224Lisa (nmn) Bailey · Bay Area Tumor Institute · UG1 · FY2020 · CA
NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans
$867,166Ruy M Ribeiro · Triad National Security, Llc · R01 · FY2025 · AI
Developing Tolerance Approaches to Overcome Humoral Immunity
$867,143Stuart Johnston Knechtle · Emory University · U19 · FY2016 · AI
Function and Differentiation
$866,753Marion Pepper · University Of Washington · R56 · FY2023 · AI
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer
$866,737Jennifer June Sessions · Cynvec, Llc · R44 · FY2022 · CA
Regulation and Function of WIP1 Phosphatase and its Role in Tumor Cells
$865,924Ettore Appella · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
$865,728Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · R35 · FY2021 · CA
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$865,682Charles Bix Shoemaker · Tufts University Boston · R01 · FY2023 · AI
How Does blockade of CD40/CD40L Prevent Autoimmunity?
$865,601La Jolla Inst For Allergy &Immunolgy · U19 · FY2001 · AI
Clinical Trials of Patients with AIDS-Related Malignancies
$865,406Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Development of botulinum neurotoxin immunotherapy
$865,401University Of California San Francisco · U01 · FY2003 · AI
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
$865,361Andrew B Mahon · Phd Skin Care Llc · R44 · FY2022 · AR
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
$865,339Andrew B Mahon · Phd Skin Care Llc · R44 · FY2023 · AR
Northern California Pediatrics AIDS Treatment Center
$865,312University Of California San Francisco · U01 · FY2003 · AI
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$865,308Avinash Desai · Actinium Pharmaceuticals, Inc. · R42 · FY2024 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$865,308Avinash Desai · Actinium Pharmaceuticals, Inc. · R42 · FY2023 · CA
Development of Drugs Acting at Adenosine Receptors
$865,266Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
$865,162Benjamin Richard Hawley · Engage Biologics Inc. · R44 · FY2025 · TR
Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform
$865,070Ian Paul Winters · D2g Oncology, Inc. · R44 · FY2021 · CA